SEC Company Response from Whitehawk Therapeutics, Inc. (WHWK) (CIK 0001422142) (WHWK) — Jun 21, 2017
Whitehawk Therapeutics, Inc. (WHWK) (CIK 0001422142)
Date: June 21, 2017 · CIK: 0001422142 · Accession: 0001193125-17-209468
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217320
Letter
Acceleration Request
Aerpio Pharmaceuticals, Inc.
9987 Carver Road
Cincinnati, OH
June 21, 2017
VIA EDGAR
Suzanne Hayes
Mary Beth Breslin
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare and Insurance
F Street, N.E.
Washington, D.C. 20549
Re: Aerpio Pharmaceuticals, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333-217320
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on June 23, 2017, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Danielle Lauzon at (617) 570-1955.
The Company hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Aerpio Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request Aerpio Pharmaceuticals, Inc. 9987 Carver Road Cincinnati, OH 45242 June 21, 2017 VIA EDGAR Suzanne Hayes Mary Beth Breslin United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare and Insurance 100 F Street, N.E. Washington, D.C. 20549 Re: Aerpio Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-217320 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on June 23, 2017, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Danielle Lauzon at (617) 570-1955. The Company hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Aerpio Pharmaceuticals, Inc. By: /s/ Joseph H. Gardner Name: Title: Joseph H. Gardner Chief Executive Officer cc: Goodwin Procter LLP